Repair Biotechnologies
repairbiotechnologies.com
Actively hiring
Health Care
Rare Disease Therapeutics
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$29.8M
10 rounds on record
Latest round
$5.3M
Venture round · Nov 2025 · 10 mo ago
Team
8
US Form 5500 (plan participants) · Dec 2025 · 0% in a year
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Nov 19, 2025
Partnership AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality · repairbiotechnologies.com
Nov 14, 2025
Raised a round Venture round $5.3M · SEC Form D
Mar 15, 2024
Raised a round Convertible Note $6.2M · SEC Form D
Jun 2, 2023
Raised a round Venture round $8.4M · SEC Form D
Feb 12, 2021
Raised a round Convertible Note $200k · SEC Form D
Aug 25, 2020
Raised a round Venture round $2.9M · SEC Form D
Mar 11, 2019
Raised a round Convertible Note $2.2M · SEC Form D
Mar 11, 2019
Raised a round Convertible Note $2.2M · SEC Form D
Jan 14, 2019
Raised a round Convertible Note $75k · SEC Form D
Jul 11, 2018
Raised a round Convertible Note $450k · SEC Form D
2018
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Nov 2025 | $5.3M | — | SEC Form D |
| Convertible Note | Mar 2024 | $6.2M | — | SEC Form D |
| Venture round | Jun 2023 | $8.4M | — | SEC Form D |
| Convertible Note | Feb 2021 | $200k | — | SEC Form D |
| Venture round | Aug 2020 | $2.9M | — | SEC Form D |
| Convertible Note | Mar 2019 | $2.2M | — | SEC Form D |
| Convertible Note | Mar 2019 | $2.2M | — | SEC Form D |
| Convertible Note | Mar 2019 | $2.2M | — | SEC Form D |
| Convertible Note | Jan 2019 | $75k | — | SEC Form D |
| Convertible Note | Jul 2018 | $450k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Repair Biotechnologies, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Reason NAExecutive Officer, DirectorSEC Form D
Guilherme Cherman Perdigao de OliveiraExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high…
Prophylix AS has entered into a definitive agreement with Rallybio, a U.S.-based drug development company, under which Rallybio acquires…
SynOx Therapeutics develops transformative therapy that helps improves the lives of TGCT patients. Learn more.
Company Overview Rooted in two decades of discovery Santero Therapeutics is a Belgian biotechnology company developing first-in-class…
About Us NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes…
News
Repair Biotechnologies Granted Rare Disease Evidence Principles (RDEP) Eligibility by the FDA for REP-0003 in Homozygous Familial Hypercholesterolemia
Repair Biotechnologies, Inc., a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, today announced that the U.S. Food and Drug Administration (FDA) has granted eligibility for the Rare Disease E
Read more
Report
AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality
HEIDELBERG, Germany - AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality. The collaboration will focus on developing and manufacturing a novel mR
Read more
Report
Repair Biotechnologies Presents Preclinical Data at American Heart Association's Scientific Sessions 2025 Showing Regression of Atherosclerotic Plaque with REP-0003 Treatment
Repair Biotechnologies, Inc. today announced the recent presentation of preclinical data at American Heart Association's (AHA) Scientific Sessions 2025, held from November 7th to 10th in New Orleans, Louisiana, supporting the ability of its drug REP-0003
Read more
Report
Repair Biotechnologies Announces Appointment of Noted Endocrinologist Prof. Frederick J. Raal to Scientific Advisory Board
Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing and stabilizing atherosclerotic plaque, today announced the appointment of Prof. Frederick J. Ra
Read more
Report
Repair Biotechnologies Receives Orphan Drug Designation from the FDA for the Treatment of Homozygous Familial Hypercholesterolemia
Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/) is a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque. The company is pleased to announce that the U.S. Food and Drug Adminis
Read more
Report
Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board
Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapi ...
Read more
Report
Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board
Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, today announced the appointment of Dr. Deepak L. Bhatt as a scientific a
Read more
Report
Repair Biotechnologies Announces Positive Pre-IND Meeting with FDA for REP-0003 to Treat Homozygous Familial Hypercholesterolemia
Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, is pleased to announce that it has received positive feedback from a Pre
Read more
Report
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis
Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive
Read more
Report
Show more news
People
Reason NA
Executive Officer, Director
Guilherme Cherman Perdigao de Oliveira
Executive Officer, Director
Guilherme Oliveira
Director
Anthony Chow
Director
Guilherme Cherman Perdigo de Oliveira
Director
Kelsey Moody
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Financials
Total raised
$29.8M
Latest round
Venture - Series Unknown
Funding rounds
10
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2025 | $5.3M | Details |
| Convertible Note | 2024 | $6.2M | Details |
| Venture - Series Unknown | 2023 | $8.4M | Details |
| Convertible Note | 2021 | $200k | Details |
| Venture - Series Unknown | 2020 | $2.9M | Details |
| Convertible Note | 2019 | $2.2M | Details |
| Convertible Note | 2019 | $2.2M | Details |
| Convertible Note | 2019 | $2.2M | Details |
| Convertible Note | 2019 | $75k | Details |
| Convertible Note | 2018 | $450k | Details |